Mutual of America Capital Management LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 164,288 shares of the biopharmaceutical company's stock after selling 2,815 shares during the period. Mutual of America Capital Management LLC's holdings in Gilead Sciences were worth $18,215,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Quotient Wealth Partners LLC boosted its position in Gilead Sciences by 7.7% in the second quarter. Quotient Wealth Partners LLC now owns 8,047 shares of the biopharmaceutical company's stock worth $892,000 after purchasing an additional 577 shares during the last quarter. Chevy Chase Trust Holdings LLC increased its position in shares of Gilead Sciences by 0.5% during the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 662,803 shares of the biopharmaceutical company's stock valued at $73,485,000 after purchasing an additional 3,440 shares during the last quarter. Arista Wealth Management LLC bought a new position in shares of Gilead Sciences in the 2nd quarter worth approximately $1,257,000. Stratos Wealth Partners LTD. boosted its holdings in shares of Gilead Sciences by 5.6% in the second quarter. Stratos Wealth Partners LTD. now owns 83,878 shares of the biopharmaceutical company's stock worth $9,300,000 after buying an additional 4,461 shares during the last quarter. Finally, Angeles Wealth Management LLC grew its position in Gilead Sciences by 69.2% during the second quarter. Angeles Wealth Management LLC now owns 3,954 shares of the biopharmaceutical company's stock valued at $438,000 after buying an additional 1,617 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.
Wall Street Analyst Weigh In
GILD has been the topic of several recent research reports. Weiss Ratings reiterated a "buy (b)" rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. The Goldman Sachs Group lifted their target price on Gilead Sciences from $105.00 to $108.00 and gave the company a "neutral" rating in a research report on Friday. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a report on Tuesday, September 16th. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Finally, Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $119.17.
Check Out Our Latest Stock Analysis on GILD
Insider Buying and Selling at Gilead Sciences
In other news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares of the company's stock, valued at approximately $66,013,726.98. The trade was a 1.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $354,240.00. Following the transaction, the insider directly owned 110,193 shares of the company's stock, valued at approximately $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,500 shares of company stock worth $8,281,540. Insiders own 0.27% of the company's stock.
Gilead Sciences Stock Performance
NASDAQ GILD opened at $122.81 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a twelve month low of $85.60 and a twelve month high of $124.11. The business has a 50-day moving average price of $115.22 and a 200-day moving average price of $110.52. The firm has a market cap of $152.38 billion, a price-to-earnings ratio of 24.46, a price-to-earnings-growth ratio of 0.84 and a beta of 0.34.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. During the same period in the previous year, the firm earned $2.01 EPS. The firm's revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
